Pharming buys their business. An OIG investigation will show that pharming pays their doctors for over 95% of patients. Quid pro quo. Pharming managers require their ruconest account managers to set up speaker events. Ruconest costs up to $500k a year for treatment.
All of their patient speakers are taking their product off label. They are all type 3 HAE patients- ruconest is not indicated for type 3. These patient speakers promote ruconest off label at all of their speaker events. Type 3 patients typically need more more product than on label patients. This is why the company made them speakers too. Quid pro quo.
These are the results that pharming delivered today. They should have done better considering the above. They genuinely believe that no one will call them out of their scandalous business practices.
Delivered 14% increase in revenue, 31% increase in operating profit and 33% increase in net profit year-on-year
All of their patient speakers are taking their product off label. They are all type 3 HAE patients- ruconest is not indicated for type 3. These patient speakers promote ruconest off label at all of their speaker events. Type 3 patients typically need more more product than on label patients. This is why the company made them speakers too. Quid pro quo.
These are the results that pharming delivered today. They should have done better considering the above. They genuinely believe that no one will call them out of their scandalous business practices.
Delivered 14% increase in revenue, 31% increase in operating profit and 33% increase in net profit year-on-year